Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • themanfromkolob themanfromkolob Dec 17, 2012 1:55 PM Flag

    Comparison TZYM and Insmed

    Tranzyme (TZYM) was a very promising drug in Phase2 lots of cash , big investment bankers. Big insider and Instity owners 27 M shares.A sure bet around 4 dollars most in for and then today Tranzyme, Inc. (TZYM) trial failure.
    tears in my beer.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Possibly you attach a different meaning to the rest of us to the term "very promising drug" -

      "Tranzyme Pharma ( TZYM ) announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy.

      Tranzyme Pharma said its decision followed a planned interim futility analysis, which examined patients' responsiveness to thrice daily oral dosing of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial. The results are consistent with the findings of a prior Phase 2b trial in that there was a very large placebo effect and no treatment effect."

 
INSM
14.35+0.41(+2.94%)12:43 PMEDT